Are Cis-Spliced Fusion Proteins Pathological in More Aggressive Luminal Breast Cancer? | Oncotarget



August 17, 2023

  • Share
  • Oncotarget #published this #editorial on June 12, 2023 in Volume 14, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?” by Chia-Chia Liu and Xiao-Song Wang from the UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA. DOI - Correspondence to - Xiao-Song Wang - Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - cancer, luminal B breast cancer, RAD51AP1-DYRK4, MEK inhibitor, chimerical transcript About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer Research

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.